Matching slides 303,780
Current window 201,901-201,930
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

201,901-201,930 of 303,780

filter-aware
07
The slide uses a visual comparison of biological mechanisms to argue for the superiority of the company's 'Decoy AXL Receptor' approach.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Agitate (Make it worse)1 hit
08
The slide uses a two-column layout to contrast the drug's engineering/profile with its biomarker/IP strategy.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Agitate (Make it worse)1 hit
09
The slide uses a standard organizational structure layout with headshots and a logo grid for credibility.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
11
The pie chart visualizes the relative size of the patient populations described in the list.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
Aravive | Investor Presentation Deck | 39 slidesAravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
13
The slide uses a process flow diagram to show the Phase 1b study arms.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
15
The slide includes two scatter plots with error bars and two summary tables of experimental data.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
17
The slide highlights clinical efficacy data from a Phase 1b trial (PROC).Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
19
Includes trial design diagram with randomization and endpoint hierarchy.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
20
The slide uses qualitative feedback from healthcare providers and KOLs to validate market demand.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
21
Aravive | Investor Presentation Deck | 39 slidesAravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
22
The slide uses a process flow diagram to illustrate the trial structure.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
23
The slide includes detailed footnotes explaining specific adverse events and patient outcomes.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
24
Includes footnotes comparing results to historical METEOR and CANTATA studies.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
25
Data compares low vs high biomarker groups across different dosage cohorts.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
26
The slide outlines a clinical trial protocol including randomization, interim analysis for accelerated approval, and primary/secondary endpoints.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
27
The slide uses a table to summarize key value propositions and speech bubbles to provide direct KOL validation.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
28
The slide features a photo of a patient being comforted, emphasizing the human element of the medical treatment.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
29
The slide outlines a standard clinical trial schema with a dose-finding/safety phase followed by a randomized efficacy phase.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
30
Data cutoff date is August 18, 2022. N=21 patients.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
31
Includes a footnote comparing results to a historical P3 study.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
34
PDAC stands for Pancreatic Ductal Adenocarcinoma. RP2D stands for Recommended Phase 2 Dose.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
35
Includes qualitative feedback from KOLs and healthcare providers regarding clinical utility and patient selection.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
36
The slide uses a horizontal timeline with four distinct time periods, each containing multiple clinical trial or regulatory events.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
37
Data as of 6/30/2022.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
38
Aravive | Investor Presentation Deck | 39 slidesAravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
39
Aravive | Investor Presentation Deck | 39 slidesAravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
02
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Situation & Context1 hit
03
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Situation & Context1 hit
04
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Situation & Context1 hit